Get the Stockscreener App
1.55
2.65%
0.04
After Hours:
1.76
0.21
+13.55%
Biocardia Inc stock is traded at $1.55, with a volume of 311.96K.
It is up +2.65% in the last 24 hours and down -27.57% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$1.51
Open:
$1.51
24h Volume:
311.96K
Relative Volume:
0.43
Market Cap:
$9.00M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.2199
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
+17.42%
1M Performance:
-27.57%
6M Performance:
-21.72%
1Y Performance:
-40.15%
1-Day Range:
$1.4054
$1.58
1-Week Range:
$1.30
$1.58
52-Week Range:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.07 | 5.67B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.22 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.13 | 109.81M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.195 | 429.79M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.08 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
Is a relief rally coming for BioCardia Inc. holdersRecession Risk & Safe Entry Point Identification - newser.com
How sentiment analysis helps forecast BioCardia Inc.July 2025 Fed Impact & Consistent Profit Alerts - newser.com
How to forecast BioCardia Inc. trends using time seriesWeekly Trade Review & AI Enhanced Market Trend Forecasts - newser.com
Why BioCardia Inc. stock could benefit from AI revolutionMarket Risk Analysis & High Accuracy Buy Signal Tips - newser.com
Will BioCardia Inc. stock attract ESG investors2025 Buyback Activity & Reliable Momentum Entry Alerts - newser.com
Top 5 Reasons to Watch TCI Finance Limited Stock Right NowEarnings Revision Updates & Explosive Capital Growth - earlytimes.in
How to manage a losing position in BioCardia Inc.Weekly Trade Recap & Entry Point Confirmation Alerts - newser.com
How BioCardia Inc. (6JU0) stock reacts to weak economyGold Moves & Weekly Chart Analysis and Guides - newser.com
What RSI levels show for BioCardia Inc. (6JU0) stockJuly 2025 Patterns & Fast Moving Trade Plans - newser.com
How to build a custom watchlist for BioCardia Inc.Quarterly Portfolio Report & AI Powered Market Entry Strategies - newser.com
Trend analysis for BioCardia Inc. this weekLong Setup & Detailed Earnings Play Alerts - newser.com
Identifying reversal signals in BioCardia Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - newser.com
Top chart patterns to watch in BioCardia Inc.Earnings Recap Report & Entry Point Confirmation Alerts - newser.com
What does recent volatility data suggest for BioCardia Inc.Weekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Will BioCardia Inc. benefit from macro trends2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
BioCardia Sets Record Date for Annual Meeting - TipRanks
BioCardia schedules annual shareholder meeting for December 2, sets proposal deadlines - Investing.com
What’s next for BioCardia Inc. stock priceTrade Exit Summary & Safe Capital Growth Tips - newser.com
Using data models to predict BioCardia Inc. stock movementMarket Growth Summary & Free High Accuracy Swing Entry Alerts - newser.com
Can you recover from losses in BioCardia Inc.Earnings Growth Report & Risk Managed Investment Entry Signals - newser.com
Ranking BioCardia Inc. among high performing stocks via toolsExit Point & Fast Gaining Stock Strategy Reports - newser.com
Institutional scanner results for BioCardia Inc.2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com
BioCardia Regains Nasdaq Compliance, Secures Continued Listing - The Globe and Mail
BioCardia Inc. stock chart pattern explainedRisk Management & Long-Term Safe Investment Ideas - newser.com
BioCardia regains Nasdaq compliance after improving finances By Investing.com - Investing.com Nigeria
BioCardia regains Nasdaq compliance after improving finances - Investing.com
BioCardia Regains Compliance with Nasdaq Listing Requirements - MarketScreener
Cardiovascular Therapeutics Developer BioCardia Successfully Maintains Nasdaq Capital Market Listing - Stock Titan
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Blank Andrew Scott | Director |
Sep 19 '25 |
Buy |
1.25 |
288,000 |
360,000 |
634,023 |
| Altman Peter | President and CEO |
Sep 19 '25 |
Buy |
1.25 |
48,000 |
60,000 |
216,762 |
| Altman Peter | President and CEO |
Aug 22 '25 |
Buy |
1.83 |
700 |
1,281 |
168,762 |
| Altman Peter | President and CEO |
Aug 13 '25 |
Buy |
1.83 |
100 |
183 |
168,062 |
| Altman Peter | President and CEO |
Aug 12 '25 |
Buy |
1.75 |
400 |
700 |
167,962 |
| Altman Peter | President and CEO |
Aug 11 '25 |
Buy |
1.76 |
1,700 |
2,989 |
167,562 |
| McClung David | Chief Financial Officer |
Jun 30 '25 |
Buy |
2.08 |
4,819 |
9,999 |
47,950 |
| Altman Peter | President and CEO |
Jun 30 '25 |
Buy |
2.08 |
24,096 |
49,999 |
165,862 |
| STERTZER SIMON H | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
192,654 |
| Blank Andrew Scott | Director |
Jun 30 '25 |
Buy |
2.08 |
72,289 |
150,000 |
346,023 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):